Chronic wounds are a growing problem in the UK, impacting on patients quality of life as well as vital healthcare resources. Preventing and managing biofilms is fast becoming a primary objective in wound care treatment. Poloxamer-based surfactants, which target biofilms, are emerging as an effective treatment of chronic wounds. Surfactants have been shown to play an active role in cleansing, desloughing, debridement, prevention, disruption and removal of biofilms. This article explores the role of biofilms in wound development — how to prevent, identify and treat them. It also looks at surfactants, such as poloxamer, which is showing promising results in the management of wound biofilm. One particular poloxamer-based surfactant, known for its anti-biofilm capabilities and contained within the UCS™ debridement cloth, is discussed in this article.
Venous leg ulcers make up a large part of a district nurse’s caseload, with the application of compression bandaging requiring competent and skilled practitioners. At Central and North West London Foundation Trust (CNWL) Camden Integrated Primary Care (IPC) Service recruiting and retaining community nurses is a challenge, a situation which is shared across all London boroughs. In particular, it is difficult to maintain consistent standards for wound cleansing and compression bandaging, resulting in the responsibility for a large caseload falling to a small number of practitioners. Following a review of innovative products on show at the European Wound Management Association (EWMA) conference in May 2014, an alternative to traditional compression bandaging was identified as a possible solution to this problem; namely, UCS™ for effective debridement and Juxta CURES™ as an alternative to compression bandaging (both medi UK Ltd, Hereford). A total of 26 patients evaluated the products, which were found to be more clinically effective than previous regimens and also resulted in substantial cost savings.
